Securian Asset Management Inc. Has $1.10 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Securian Asset Management Inc. lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,415 shares of the medical equipment provider’s stock after selling 2,152 shares during the quarter. Securian Asset Management Inc.’s holdings in Hologic were worth $1,101,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. acquired a new position in Hologic during the 4th quarter valued at about $27,000. Venturi Wealth Management LLC bought a new position in Hologic in the third quarter valued at approximately $29,000. NBC Securities Inc. acquired a new stake in Hologic during the 3rd quarter worth $33,000. Deseret Mutual Benefit Administrators raised its position in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its position in shares of Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 227 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX opened at $74.85 on Tuesday. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $82.45. The firm has a fifty day simple moving average of $76.22 and a 200 day simple moving average of $73.76. The stock has a market capitalization of $17.47 billion, a price-to-earnings ratio of 38.19, a PEG ratio of 2.50 and a beta of 1.01.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the company earned $1.06 EPS. Hologic’s revenue for the quarter was down .8% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. UBS Group increased their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Evercore ISI boosted their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. JPMorgan Chase & Co. increased their target price on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic currently has an average rating of “Moderate Buy” and an average price target of $85.60.

Insider Transactions at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.